


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On FEBRUARY 12, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Sharon Soriano



Box-528 1642
PATENT
Attorney Docket No.: 014058-009810US
Client Reference No.: CX-98-0028

RECEIVED

MAR 01 2001

TECH CENTER 1600/29.

#8a 3/3/01
T. Gray

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CHEEVER and GHEYSEN

Application No.: 09/493,480

Filed: January 28, 2000

For: HER-2/NEU FUSION PROTEINS

Examiner: Hunt, Jennifer

Art Unit: 1642

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

RECEIVED

FEB 27 2001

TECH CENTER 1600/2900

Box SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Examiner's Communication mailed December 12, 2000, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

- On page 6, line 7, insert --(SEQ ID NO:1)-- after "human HER-2/neu protein".
- On page 6, line 21, insert --(SEQ ID NO:11)-- after "mouse Her-2/neu".
- On page 6, line 22, insert --(SEQ ID NO:14)-- after "mouse Her-2/neu".